Skip to main content


Page 2 of 8

  1. Systemic sclerosis (SSc) is a rare autoimmune disorder characterized by vascular and fibrosing involvement of the skin and internal organs. In this study, we determined the prevalence and characteristics of ra...

    Authors: Fatemeh Badiee, Alireza Fatemi, Reza Zahedpasha, Mohammad Hadi Gharib, Mohammadhassan Jokar, Somayeh Livani, Mehrdad Aghaie and Nafiseh Abdolahi
    Citation: BMC Rheumatology 2023 7:9
  2. Drug-related problems can negatively influence treatment outcome and well-being for patients with rheumatic diseases. Thus, it is important to support patients in preventing or resolving drug-related problems ...

    Authors: Lex L. Haegens, Victor J. B. Huiskes, Elisabeth M. Smale, Charlotte L. Bekker and Bart J. F. van den Bemt
    Citation: BMC Rheumatology 2023 7:7
  3. The nature of the deposits in immune-mediated glomerulonephritis with a membranous pattern and masked IgG-Kappa deposits (MGMID) remains still to be elucidated.

    Authors: Savino Sciascia, Paolo Miraglia, Massimo Radin, Manuela Giarin, Nicolas Charbonier, Antonella Barreca, Irene Cecchi, Irene Lanzetta, Roberta Fenoglio, Elisa Menegatti and Dario Roccatello
    Citation: BMC Rheumatology 2023 7:6
  4. Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators. This p...

    Authors: Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman and Jeffrey R. Curtis
    Citation: BMC Rheumatology 2023 7:5
  5. The effects and their magnitudes of sex on disease activity indices for rheumatoid arthritis are not clear. We aimed to comprehensively evaluate the influence of sex on disease activity indices in the real-wor...

    Authors: Takahiro Nishino, Atsushi Hashimoto, Shigeto Tohma and Toshihiro Matsui
    Citation: BMC Rheumatology 2023 7:4
  6. Patient and public involvement (PPI) in every aspect of research will add valuable insights from patients’ experiences, help to explore barriers and facilitators to their compliance/adherence to assessment and...

    Authors: Ashokan Arumugam, Lawrence Rick Phillips, Ann Moore, Senthil D. Kumaran, Kesava Kovanur Sampath, Filippo Migliorini, Nicola Maffulli, Bathri Narayanan Ranganadhababu, Fatma Hegazy and Angie Botto-van Bemden
    Citation: BMC Rheumatology 2023 7:2
  7. Aotearoa New Zealand (AoNZ) has no agreed models for rheumatology service provision in government-funded health care. We aimed to describe what people with inflammatory rheumatic diseases who have used rheumat...

    Authors: Rachel Ngan Kee, Valerie Milne, Nicola Dalbeth and Rebecca Grainger
    Citation: BMC Rheumatology 2023 7:1
  8. Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, but the prevalence in Australia is unknown. We estimated RA period prevalence and identified factors associated with frequent RA hospi...

    Authors: Khalid Almutairi, Charles Inderjeeth, David B Preen, Helen Keen and Johannes Nossent
    Citation: BMC Rheumatology 2022 6:93
  9. Systemic lupus erythematosus or lupus is a severe chronic autoimmune disorder that disproportionately impacts young African Americans. Increasing lupus awareness in this high-risk group may be an effective app...

    Authors: Edith M. Williams, Joni Nelson, Diane Francis, Keesha Corbin, Gary Link, Tomika Caldwell and Gary Gilkeson
    Citation: BMC Rheumatology 2022 6:92
  10. Bone erosions may appear early or later during rheumatoid arthritis (RA), causing joint damage and functional impairment. However, in some patients erosions do not occur, even after several years of disease. T...

    Authors: Björn Svensson, Maria L. E. Andersson, Inger Gjertsson, Ingiäld Hafström, Sofia Ajeganova and Kristina Forslind
    Citation: BMC Rheumatology 2022 6:88
  11. COVID-19 is associated with a postinfectious hyperinflammatory disorder, multisystem inflammatory syndrome in children (MIS-C), that shares characteristics with still’s disease, known as systemic juvenile idio...

    Authors: Maya Alexandri, Julisa Patel, Eli Paul and Lynne W. Coule
    Citation: BMC Rheumatology 2022 6:87
  12. To determine whether there were improvements in rheumatology care for rheumatoid arthritis (RA) between 2002 and 2019 in Ontario, Canada, and to evaluate the impact of rheumatologist regional supply on access.

    Authors: Claire E. H. Barber, Diane Lacaille, Ruth Croxford, Cheryl Barnabe, Deborah A. Marshall, Michal Abrahamowicz, Hui Xie, J. Antonio Avina-Zubieta, John M. Esdaile, Glen Hazlewood, Peter Faris, Steven Katz, Paul MacMullan, Dianne Mosher and Jessica Widdifield
    Citation: BMC Rheumatology 2022 6:86
  13. Although drug treatment strategies for rheumatoid arthritis (RA) are relatively well established, there is a paucity of evidence on the treatment in older patients. The purpose of this study is to build a regi...

    Authors: Masayo Kojima, Yutaka Kawahito, Takahiko Sugihara, Toshihisa Kojima, Ryozo Harada, Shintaro Hirata, Motomu Hashimoto, Toshihiko Hidaka, Hajime Ishikawa, Hiromu Ito, Mitsumasa Kishimoto, Yuko Kaneko, Kazuo Matsui, Toshihiro Matsui, Isao Matsushita, Akio Morinobu…
    Citation: BMC Rheumatology 2022 6:90
  14. Biologic and targeted synthetic disease modifying agents (b/tsDMARDs) have broadened the treatment landscape for autoimmune diseases particularly in patients refractory to conventional DMARDs. More recently, t...

    Authors: Thomas Khoo, Navkiran Sidhu, Franca Marine, Susan Lester, Alannah Quinlivan, Debra Rowett, Rachelle Buchbinder and Catherine L. Hill
    Citation: BMC Rheumatology 2022 6:79
  15. Rheumatoid arthritis (RA) is commonly associated with higher rates of comorbidities. Recent recommendations highlight screening comorbidities during the disease course because of their impact on patients’ abil...

    Authors: Aicha Ben Tekaya, Emna Hannech, Olfa Saidane, Leila Rouached, Selma Bouden, Rawdha Tekaya, Ines Mahmoud and Leila Abdelmoula
    Citation: BMC Rheumatology 2022 6:78
  16. The outbreak of severe acute respiratory syndrome coronavirus 2 has had an enormous impact on global health. Vaccination remains one of the most effective interventions for disease prevention. Clinically signi...

    Authors: Meghan Corrigan Nelson, Heather Rytting, Larry A. Greenbaum and Baruch Goldberg
    Citation: BMC Rheumatology 2022 6:81
  17. Assessing medication adherence in rheumatoid arthritis (RA) is clinically significant as low adherence is associated with high disease activity. Self-reported medication adherence surveys have been shown to ha...

    Authors: Nobuyuki Yajima, Takashi Kawaguchi, Ryo Takahashi, Hiroki Nishiwaki, Yoichi Toyoshima, Koei Oh, Tsuyoshi Odai, Takayuki Kanai, Donald E. Morisky, Takuhiro Yamaguchi and Tsuyoshi Kasama
    Citation: BMC Rheumatology 2022 6:75
  18. Some composite measures for determining the treatment effects of disease-modifying antirheumatic drugs on remission and low disease activity (LDA) in rheumatoid arthritis (RA) may produce misleading results if...

    Authors: Kirsten Janke, Corinna Kiefer, Natalie McGauran, Bernd Richter, Dietmar Krause and Beate Wieseler
    Citation: BMC Rheumatology 2022 6:82
  19. This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA).

    Authors: Hideo Sakane, Koichi Okamura, Makoto Inoue, Hiroshi Inoue, Yukio Yonemoto, Hirofumi Mitomi, Kosei Tsuchida, Takahito Suto, Tetsuya Kaneko and Hirotaka Chikuda
    Citation: BMC Rheumatology 2022 6:74
  20. Rituximab (RTX), anti-CD 20 monoclonal antibodies, has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited due to financial constrain. Biosimilar RTX may increase access b...

    Authors: Wanruchada Katchamart, Pintip Ngamjanyaporn, Annop Orawongpaisarn, Thossapoom Phubangkertphon, Sasimon Borrirukwisitsak and Nichapa Dechapaphapitak
    Citation: BMC Rheumatology 2022 6:77
  21. The use of frequent electronic patient reported outcome measures (ePRO’s) enables monitoring disease activity at a distance (telemonitoring) in patients with inflammatory arthritis. However, telemonitoring stu...

    Authors: J. Wiegel, B. F. Seppen, M. T. Nurmohamed, W. H. Bos and M. M. ter Wee
    Citation: BMC Rheumatology 2022 6:73
  22. Although patients with rheumatic and musculoskeletal diseases (RMDs) are at increased risk for adverse outcomes of COVID-19 illness compared to healthy controls, they also have lower rates of willingness to be...

    Authors: Yomei P. Shaw, Sara Hustek, Nina Nguyen, Makenzie Starlin, Kristin Wipfler, Beth I. Wallace and Kaleb Michaud
    Citation: BMC Rheumatology 2022 6:76
  23. Involving patients and members of the public in healthcare planning is beneficial for many reasons including that the outcomes focus on topics relevant to service users. The National Early Inflammatory Arthrit...

    Authors: Sarah Oyebanjo, Paul Amlani-Hatcher, Ruth Williams, Roger Stevens, Tom Esterine, Kate Wilkins, Clare Jacklin, Jill Hamilton, Rosie Fairfax and Heidi Lempp
    Citation: BMC Rheumatology 2022 6:89
  24. The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact r...

    Authors: Mohammed A. Omair, Hanan Al Rayes, Joanne Khabsa, Sally Yaacoub, Sultana Abdulaziz, Ghada A. Al Janobi, Abdulaziz Al Khalaf, Bader Al Mehmadi, Mahasin Al Nassar, Faisal AlBalawi, Abdullah S. AlFurayj, Ahmed Hamdan Al-Jedai, Haya Mohammed Almalag, Hajer Yousef Almudaiheem, Ali AlRehaily, Mohammed A. Attar…
    Citation: BMC Rheumatology 2022 6:70
  25. The 28-joint disease activity score (DAS28) is a widely used measure to assess disease activity in rheumatoid arthritis (RA). The DAS28-P index, a derived proportion of the patient-reported components (joint t...

    Authors: Huai Leng Pisaniello, Samuel L. Whittle, Susan Lester, Fiona Menz, Robert Metcalf, Leah McWilliams, Catherine L. Hill and Susanna Proudman
    Citation: BMC Rheumatology 2022 6:67
  26. Juvenile idiopathic arthritis (JIA) is a childhood autoimmune disease that causes swelling and pain in at least one joint. Young people with JIA experience symptoms that persist into adulthood, and thus will u...

    Authors: Gillian R. Currie, M. Harris, L. McClinton, N. Trehan, A. Van Dusen, M. Shariff, T. Kuzmyn and D. A. Marshall
    Citation: BMC Rheumatology 2022 6:85
  27. Immune checkpoint inhibitors (ICIs) enhance the immune system’s ability to target and destroy cancer cells, but this non-specific immune overactivation can result in immune-related adverse events (irAEs). Pati...

    Authors: Amanda Lusa, Carolina Alvarez, Shruti Saxena Beem, Todd A. Schwartz and Rumey Ishizawar
    Citation: BMC Rheumatology 2022 6:64
  28. Although short-term clinical trials have demonstrated that switching from infliximab (INF) bio-originator to its biosimilar is safe with no significant loss of efficacy, there are limited real-world data compa...

    Authors: Chibuike J. Alanaeme, Sujith Sarvesh, Cynthia Y. Li, Sasha Bernatsky, Jeffrey R. Curtis and Huifeng Yun
    Citation: BMC Rheumatology 2022 6:65
  29. Fibromyalgia is a chronic disease with a high burden. We aim to be the first to investigate the prevalence of fibromyalgia (FM) in Syria and assess its risk factors.

    Authors: Mhd Amin Alzabibi, Mosa Shibani, Tamim Alsuliman, Hlma Ismail, Suja alasaad, André Torbey, Abdallah Altorkmani, Bisher Sawaf, Rita Ayoub, Naram khalayli and Mayssoun Kudsi
    Citation: BMC Rheumatology 2022 6:62
  30. Rheumatoid arthritis (RA) is one of the most common chronic non-organ-specific autoimmune diseases; meanwhile, autoimmune thyroid disease (AITD) is the most common organ-specific autoimmune disease that can le...

    Authors: Mahsa Bagherzadeh-Fard, Mohammad Amin Yazdanifar, Mohammad Aghaali and Maryam Masoumi
    Citation: BMC Rheumatology 2022 6:63
  31. Advances in musculoskeletal (MSK) research have been successfully curated into widely endorsed evidence-based recommendations and guidelines. However, there continues to exist significant variations in care an...

    Authors: Opeyemi O. Babatunde, Shoba Dawson, June Brammar, Linda Parton, Krysia Dziedzic and Adewale O. Adebajo
    Citation: BMC Rheumatology 2022 6:84
  32. Rheuma Tolerance for Cure (RTCure) is a five-year international collaboration between academia, industry and patients/members of the public. It focuses on developing approaches to predict the onset of rheumato...

    Authors: Savia de Souza, Eva C. Johansson, Susanne Karlfeldt, Karim Raza and Ruth Williams
    Citation: BMC Rheumatology 2022 6:83
  33. Compared to the healthy population, the psychological impact of rheumatoid arthritis(RA) on patients' lives could dramatically lower their oral health-related quality of life (OHRQoL). Our goal is to analyze O...

    Authors: Amirhossein Parsaei, Aida Mehdipour, Hamidreza Ghadimi, Ashkan Mohammadi Kooshki, Parisa Shajari, Maryam Masoumi, Pouya Torabi, Hossein Azizi, Behnam Amini, Hanie Karimi, Hojat Dehghanbanadaki, Mohammad Aghaali and Soroush Moradi
    Citation: BMC Rheumatology 2022 6:61
  34. There is scant research about laboratory monitoring in people taking conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) for rheumatic disease. Our objective was to conduct a scoping study...

    Authors: James J. Tsakas, David F. L. Liew, Cameron L. Adams, Catherine L. Hill, Susanna Proudman, Samuel Whittle, Rachelle Buchbinder and Philip C. Robinson
    Citation: BMC Rheumatology 2022 6:59
  35. For many children and young people (CYP) with paediatric rheumatic conditions, glucocorticoid medications and their associated side-effects have a substantial impact on disease experience. Whilst there are phy...

    Authors: S. Singhal, E. M. D. Smith, L. Roper and C. E. Pain
    Citation: BMC Rheumatology 2022 6:80
  36. A treat-to-target (T2T) approach, where treatment is escalated until a specific target is achieved, and re-escalated if the target is lost, has been proposed as a strategy to improve Childhood Systemic Lupus E...

    Authors: R. S. Elliott, E. Taylor, J. Ainsworth, J. Preston and E. M. D. S. Smith
    Citation: BMC Rheumatology 2022 6:69
  37. This longitudinal study investigated whether changes in autonomous and controlled motivation to reduce sedentary behaviour were associated with variability in sedentary, standing and stepping time and, in turn...

    Authors: Ciara M. O’Brien, Joan L. Duda, George D. Kitas, Jet J. C. S. Veldhuijzen van Zanten, George S. Metsios and Sally A. M. Fenton
    Citation: BMC Rheumatology 2022 6:58
  38. Empirical evidence for effective patient-researcher collaboration in basic research is lacking. This study aims to explore good working models and impact of patient involvement in basic rheumatology research a...

    Authors: Maarten P. T. de Wit, M. I. Koenders, Y. Neijland, F. H. J. van den Hoogen, P. M. van der Kraan, F. A. J. van de Loo, H. Berkers, M. Lieon, A. van Caam and C. van den Ende
    Citation: BMC Rheumatology 2022 6:66
  39. Gout may be associated with an increased incidence of mental health disorders, however, published findings have been limited and inconsistent. Therefore, our objective was to conduct a population-based cohort ...

    Authors: Alyssa Howren, Eric C. Sayre, Hyon K. Choi, J. Antonio Avina-Zubieta, Kam Shojania, Jamie Y. Park and Mary A. De Vera
    Citation: BMC Rheumatology 2022 6:56
  40. JAK inhibitors are a relatively new class of medications that may be useful in the treatment of moderate-to-severe psoriasis and psoriatic arthritis (PsA). The objective of this study was to determine the effi...

    Authors: Samantha Sarabia, Brandan Ranjith, Sahil Koppikar and Don Thiwanka Wijeratne
    Citation: BMC Rheumatology 2022 6:71
  41. Osteoarthritis is associated with obesity, dyslipidemia and cardiovascular diseases. It has been hypothesized that L-carnitine can improve cardiovascular risk factors. We aimed to investigate the effect of L-c...

    Authors: Abbas Ali Sangouni, Farnaz Baghban, Maryam Khosravi, Hassan Mozaffari-Khosravi, Ali Dehghan and Mahdieh Hosseinzadeh
    Citation: BMC Rheumatology 2022 6:53
  42. Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real...

    Authors: Delia Colombo, Micol Frassi, Giusy Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone…
    Citation: BMC Rheumatology 2022 6:57
  43. The rapid spread of COVID-19 required swift action to provide people with rheumatic and musculoskeletal diseases (RMDs) with reliable information. People with limited health literacy constitute a vulnerable gr...

    Authors: Mark Matthijs Bakker, Tess Luttikhuis, Polina Putrik, Isabelle Jansen, Jany Rademakers, Maarten de Wit and Annelies Boonen
    Citation: BMC Rheumatology 2022 6:52
  44. Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis b...

    Authors: Ana-Maria Orbai, Philip J. Mease, Philip S. Helliwell, Oliver FitzGerald, Dona L. Fleishaker, Rajiv Mundayat and Pamela Young
    Citation: BMC Rheumatology 2022 6:68
  45. Fibromyalgia (FM) as a prototypical nociplastic pain condition displays a difficult therapeutic situation in many cases. Given the promising data on the effect of vitamin B12 in improving pain and cognitive fu...

    Authors: Faeze Gharibpoor, Banafsheh Ghavidel-Parsa, Nazila Sattari, Ali Bidari, Fatemeh Nejatifar and Ali Montazeri
    Citation: BMC Rheumatology 2022 6:51
  46. Authors: Shereen Paramalingam, Merrilee Needham, Sarah Harris, Susan O’Hanlon, Frank Mastaglia and Helen Keen
    Citation: BMC Rheumatology 2022 6:72

    The original article was published in BMC Rheumatology 2022 6:47

Annual Journal Metrics

  • 2022 Citation Impact
    2.2 - 2-year Impact Factor
    2.9 - 5-year Impact Factor
    0.891 - SNIP (Source Normalized Impact per Paper)
    0.703 - SJR (SCImago Journal Rank)

    2023 Speed
    24 days submission to first editorial decision for all manuscripts (Median)
    247 days submission to accept (Median)

    2023 Usage 
    294 Altmetric mentions 

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal